Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis (Q37999957)

26 August 2017

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis (English)

1 reference

26 August 2017

3

1 reference

26 August 2017

12

1 reference

26 August 2017

17

1 reference

26 August 2017

16

R A Kyle

1 reference

26 August 2017

13

M Gertz

1 reference

26 August 2017

R L Comenzo

1

1 reference

26 August 2017

D Reece

2

1 reference

26 August 2017

D Seldin

4

1 reference

26 August 2017

V Sanchorawala

5

1 reference

26 August 2017

H Landau

6

1 reference

26 August 2017

R Falk

7

1 reference

26 August 2017

K Wells

8

1 reference

26 August 2017

A Solomon

9

1 reference

26 August 2017

A Wechalekar

10

1 reference

26 August 2017

J Zonder

11

1 reference

26 August 2017

H Streicher

14

1 reference

26 August 2017

M Skinner

15

1 reference

26 August 2017

5 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

26

1 reference

26 August 2017

2317-2325

1 reference

26 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2012.100

26 August 2017

0 references

cites work

Amyloidosis: is a cure possible?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Molecular mechanisms of amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Monoclonal gammopathies of undetermined significance: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Diagnosis and management of the cardiac amyloidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Radioimmunodetection of amyloid deposits in patients with AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Light and electron microscopy immunohistochemical characterization of amyloid deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

Advances in the treatment of amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

7 January 2021

Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

7 January 2021

Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

7 January 2021

Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

7 January 2021

Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

7 January 2021

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.100

7 January 2021

Identifiers

DOI

10.1038/LEU.2012.100

1 reference

release_bjw7iydsnnfthbabtlrqyzybj4

26 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bjw7iydsnnfthbabtlrqyzybj4

24 November 2022

mapped directly with Wikidata item

1 reference